|1.||Kim, Yoon-Goo: 2 articles (01/2004 - 10/2003)|
|2.||Liu, Xian-rong: 1 article (01/2006)|
|3.||Mi, Xu-hua: 1 article (01/2006)|
|4.||Li, Zi: 1 article (01/2006)|
|5.||Su, Bai-hai: 1 article (01/2006)|
|6.||Fan, Jun-ming: 1 article (01/2006)|
|7.||Abdel-Naeem, Nareman M: 1 article (12/2005)|
|8.||Harba, Tarek M: 1 article (12/2005)|
|9.||Abdel-Hady, Afaf A: 1 article (12/2005)|
|10.||Kandell, Nagwa F: 1 article (12/2005)|
|2.||Chronic Kidney Failure (Chronic Renal Failure)
01/01/1998 - "In the present study, a hemofiltration technique that uses both convection and diffusion, with a double chamber hemodialyzer composed of high-flux polysulphone and hemophan (paired filtration dialysis--PFD) was evaluated with regard to the beta2M removal capacity during PFD in 8 stable ESRD patients. "
09/01/2004 - "We have evaluated plasma levels of sgp130 in 18 ESRD patients regularly dialyzed with hemophan membranes (HE) and in 15 patients dialyzed with more biocompatible synthetic membranes (BIO). "
11/01/2004 - "In this study we evaluated sgp130 release by peripheral blood mononuclear cells (PBMC) harvested from 10 healthy controls (CON) and 11 end-stage renal disease (ESRD) patients undergoing renal dialysis therapy RDT) with cellulosic hemophan membrane (HD). "
01/01/1997 - "The effects of recombinant human erythropoietin (r-HuEPO) administration on adequacy of hemodialysis (HD) during single-use versus multiple-reuse of hemophan hollow-fiber dialyzers were assessed in 16 stable end-stage renal disease (ESRD) patients. "
12/01/2005 - "One hundred subjects were selected; 20 healthy controls, 20 chronic renal failure (CRF) patients on conservative drug management and 60 CRF patients on maintenance HD (20 dialyzed by polysulfone, 20 by hemophan and 20 by cuprophane membranes). "
02/01/1993 - "Dialyzers with intermediate complement-activating potential such as cellulose acetate (CA-110; Baxter) and Hemophan (HT-100; Baxter) produced small to moderate degrees of neutropenia and small increases in thromboxane and mean pulmonary artery pressure. "
01/01/1992 - "We have undertaken a clinical study of four cellulose-based membranes (Cuprophan, Hemophan, cellulose acetate, and cellulose triacetate) in which the hydroxyl groups of the membrane have been replaced and the magnitude of replacement has varied from less than 1% to greater than 80%, to assess the role that these modifications play in functional performance, biocompatibility (neutropenia, leukocyte activation, anaphylatoxin generation, and hypoxaemia). "
10/01/2003 - "In this review, current strategies to minimize bleeding complications and our experience of haemodialysis using heparin-bound Hemophan will be discussed."
10/01/2003 - "We designed more simplified heparin binding technique and have performed haemodialysis using heparin-bound Hemophan in patients at risk of bleeding during the past 7 years. "
10/01/2003 - "Haemodialysis using heparin-bound Hemophan has been reported to be a possible modality for patients at risk of bleeding. "
01/01/2004 - "Since heparin can bind to Hemophan, hemodialysis using heparin-bound Hemophan (HBH-HD) could be a useful modality in patients at risk of bleeding. "
01/01/2004 - "Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding."
01/01/2006 - "One hundred and twenty-eight cases were divided into 6 groups: non-dialysis uremia group (n=25), peritoneal dialysis group (n=19), hemophan(Hem) membrane dialysis group (n=25), polyamide (PS) membrane dialysis group (n=25), diabetes with normal renal function group (n= 23) and normal control group (n=11). "
|1.||Peracetic Acid (Peroxyacetic Acid)
|3.||polysulfone P 1700 (UDEL)
|5.||Cytokine Receptor gp130
|1.||Renal Dialysis (Hemodialysis)